Skip to main content

Ionis Pharmaceuticals Value Stock - Dividend - Research Selection

Ionis Pharmaceuticals

ISIN: US4622221004, WKN: A2ACMZ

Market price date: 02.06.2021
Market price: 35,68 USD




Ionis Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 02-03-2021
Cash flow
Net operating cash flow 35.892.000
Capital Expenditures -35.120.000
Free cash flow 772.000
Balance sheet
Total Equity 843.347.000
Liabilities & Shareholders equity 2.389.750.000
Income statement
Net income -451.286.000
Eps (diluted) -3,230
Diluted shares outstanding 140.366.000
Net sales/revenue 729.264.000

Fundamental ratios calculated on: 02-06-2021

Ratios
Key figures 02-06-2021
Cash flow
P/C 139,54
   
P/FC 6.487,38
Balance sheet
ROI-18,88
ROE35,29
Income statement
P/E-11,05
Div. Yield0,00%
P/B5,94
P/S6,87


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolIONS
Market Capitalization5.008.259.072,00 USD
Country
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.isispharm.com


Description of the company

Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company's Ionis Core segment is developing a drug discovery platform. The Company's Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.isispharm.com